Abstracts Archive - Page 379 of 1683 - ATC Abstracts

2020 American Transplant Congress
Anticoagulation in Simultaneous Pancreas Kidney (SPK) Transplantation- On What Basis?
J. Gopal, P. Herbert, J. Crane, F. Dor, V. Papalois, A. Muthusamy
Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
*Purpose: Despite technical refinements, early pancreas graft loss due to thrombosis continues to occur. Conventional coagulation tests do not detect hypercoagulability and hence is left…
2020 American Transplant Congress
Value of dd-cfDNA When Considering Recipient Ethnicity to Further to Help Risk Stratify Transplant Recipients
A. Langone¹, B. Fischbach², D. Cohen³
¹Vanderbilt Health, Nashville, TN, ²Baylor Scott & White Health, Fort Worth, TX, ³Columbia University, New York, NY
*Purpose: Within the modern era of kidney transplantation, African American (AA) transplant recipients continue to experience disproportionately higher rates of allograft loss. A combination of…
2020 American Transplant Congress
A Novel Formula to Determine Optimal Immunosuppression in Renal Transplant Recipients Treated with Tacrolimus and Mycophenolate Mofetil: Towards Individualized Immunosuppression
O. Pankewycz¹, M. Laftavi¹, E. Onan², D. Rucker¹, D. Wang¹, K. Bhuta¹, R. Gruessner³, A. Gruessner³
¹SUNY, Upstate Medical University, Syracuse, NY, ²Cukurova University, Adana, Turkey, ³SUNY, Downstate Medical University, New York, NY
*Purpose: Tacrolimus (TAC) and mycophenolic acid (MPA) remain the most commonly used drug combination for kidney transplant immunosuppression. Adequate drug dosing is challenging due to…
2020 American Transplant Congress
Donor-Derived Cell-Free DNA May Not Discriminate Rejection in Kidney Transplant Recipients with a Prior Allograft in Place
A. Vo, M. Gillespie, S. C. Jordan, A. Peng, R. Najjar, S. Sethi, K. Lim, N. Ammerman, E. Huang
Cedars-Sinai, Los Angeles, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is an injury biomarker discriminating rejection in kidney transplant (KTx) patients (pts). However, its performance when stratified by rejection risk…
2020 American Transplant Congress
Results of Pancreas Transplantation in Diabetic Patients with End-Stage Kidney Disease Older Than 50 Years
E. Montagud-Marrahi¹, A. Molina², A. Pané³, M. Ramirez-Bajo⁴, A. Amor³, E. Esmatjes³, J. Ferrer⁵, F. Diekmann¹, P. Ventura-Aguiar¹
¹Nephrology and Kidney Transplantation Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Servei de Nefrologia i Trasplantament Renal, Hospital Clínic de Barcelona, Barcelona, Spain, ³Endocrinology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Laboratori Experimental de Nefrologia I Trasplantament (LENIT), CRB CELLEX, Fundació Clínic, IDIBAP, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Hepatobiliopancreatic and Liver Transplant Department, Hospital Clínic de Barcelona, Barcelona, Spain
*Purpose: Improvement of care in type 1 diabetes mellitus, with the optimization of patient access to insulins of variable action, has led to macro- and…
2020 American Transplant Congress
The Role of Complement-Split Products as Biomarkers for Acute Antibody-Mediated Rejection of Kidney Allografts
B. G. Abu Jawdeh¹, B. Campos-Naciff¹, K. Harrison¹, K. Meganathan¹, A. Kumar², M. Anand¹, A. Govil¹, E. S. Woodle¹, B. P. Dixon³
¹University of Cincinnati, Cincinnati, OH, ²All India Institute of Medical Sciences, New Delhi, India, ³University of Colorado, Aurora, CO
*Purpose: Acute antibody-mediated rejection (AMR) is mediated by the activation of the classical complement system in addition to non-complement dependent inflammatory pathways. Complement fixation by…
2020 American Transplant Congress
Use of Donor-Derived Cell-Free DNA Assay to Monitor Treatment Response to Allograft Rejection in Pediatric Renal Transplant Recipients
J. Steggerda¹, H. Phan Pizzo², J. Garrison², X. Zhang³, M. Haas⁴, I. Kim¹, S. Jordan¹, D. Puliyanda²
¹Comprehensive Transplant Center, Cedars Sinai Medical Center, West Hollywood, CA, ²Pediatric Nephrology, Cedars Sinai Medical Center, West Hollywood, CA, ³HLA Laboratory, Cedars-Sinai Med Center, West Hollywood, CA, ⁴Pathology, Cedars Sinai Medical Center, West Hollywood, CA
*Purpose: Acute rejection (AR) accounts for 13%-21% of graft failure in pediatrics (peds), with the number, severity, and response to treatment being a major determinant…
2020 American Transplant Congress
Single Cell RNA Sequencing of Murine Kidney Allografts Identifies Macrophage Gene Signature Associated with Acute Rejection
A. Dangi¹, N. Natesh², M. Monal¹, J. Wang³, X. Shen², X. Luo¹
¹Nephrology/Medicine, Duke University, Durham, NC, ²Biomedical Engineering, Duke University, Durham, NC, ³Surgery, Duke University, Durham, NC
*Purpose: Evaluating kidney allografts using single cell RNA sequencing (scRNAseq) can provide a comprehensive qualitative and quantitative gene expression data on thousands of individual cells.…
2020 American Transplant Congress
Attempted Validation of Lims1 Variant Rs893403 with Acute Rejection Risk
W. S. Oetting¹, G. Weihua¹, C. R. Dorr¹, R. B. Mannon², A. J. Matas¹, P. A. Jacobson¹, A. K. Israni¹
¹University of Minnesota, Minneapolis, MN, ²University of Alabama, Birmingham, AL
*Purpose: Acute rejection (AR) in kidney allograft recipients is a significant risk factor for reduced graft survival. Identifying individuals at risk for AR could facilitate…
2020 American Transplant Congress
Natural Course of Borderline Changes in Kidney Allografts: A MMDx Study
P. Hruba¹, K. S. Madill-Thomsen², M. Mackova², J. Maluskova³, E. Honsova³, J. Slatinska⁴, P. F. Halloran², O. Viklicky⁴
¹Transplant Laboratory, IKEM, Prague, Czech Republic, ²ATAGC, University of Alberta, Edmonton, AB, Canada, ³Department of Pathology, IKEM, Prague, Czech Republic, ⁴Department of Nephrology, IKEM, Prague, Czech Republic
*Purpose: Molecular assessment of kidney allograft biopsies with Banff borderline changes (BL) category has showed only 30% of rejection phenotype in various post-transplant follow-up and…